Compares treatment approaches and outcomes in people with acute ischemic stroke
Collects information on adults with acute ischemic stroke receiving different treatments over time.
Plain-language title generated from the registry record
Registry title: Different Treatment Strategies on Prognosis of Acute Ischemic Stroke(AISDTS)
Key facts
- Where
- Nanjing, ChinaSee the site
Where in China
- Nanjing First Hospital, Nanjing Medical UniversityNanjing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nanjing First Hospital, Nanjing Medical University
- Trial code
- NCT05410457
- Record updated
- 9 April 2026
- Original description
AISDTS is a prospective registry study, in which clinical information, examination and imaging data of patients with acute ischemic stroke receiving different treatment strategies were collected, grouped and statistically analyzed, and corresponding clinical prediction models were constructed to explore the role of clinical biological indicators in the occurrence and development of stroke.Read full original descriptionShow less
Study on the Effect of Different Treatment Strategies on Prognosis of Acute Ischemic Stroke(AISDTS)
AISDTS is a prospective registry study, in which clinical information, examination and imaging data of patients with acute ischemic stroke receiving different treatment strategies were collected, grouped and statistically analyzed, and corresponding clinical prediction models were constructed to explore the role of clinical biological indicators in the occurrence and development of stroke.
Inclusion: A) ≥18 years of age; B) hospital admission for ischemic stroke; C) Signed informed consent.
Exclusion: A) patients with incomplete clinical information; B) hospitalization observation time less than 24 hours; C) recent trauma, severe inflammation, severe liver and kidney dysfunction, progressive malignance and other serious diseases; D) baseline mRS score>2; E) informed consent is not signed.